Related Experiment Video
Updated: Jan 27, 2026

Isolation and Characterization of Human Umbilical Cord-derived Mesenchymal Stem Cells from Preterm and Term Infants
Published on: January 26, 2019
Rifampin Pharmacokinetics and Safety in Preterm and Term Infants
P Brian Smith1,2, C Michael Cotten2, Mark L Hudak3
1Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA brian.smith@duke.edu.
Insights
Intravenous rifampin dosing for infants was studied. Weight and postnatal age-based regimens achieved adult-like exposures for treating staphylococcal infections and tuberculosis (TB) safely.
Area of Science:
- Pharmacology
- Neonatal Medicine
- Infectious Diseases
Background:
- Rifampin is crucial for treating methicillin-resistant staphylococcal infections and tuberculosis (TB).
- Limited pharmacokinetic data exists for intravenous rifampin in neonates.
- Optimizing infant dosing is essential for effective treatment and safety.
Purpose of the Study:
- To evaluate the pharmacokinetics (PK) and safety of intravenous rifampin in infants.
- To develop weight and postnatal age-based dosing regimens for neonates.
- To compare infant rifampin exposure to adult therapeutic levels.
Main Methods:
- A multicenter, prospective pharmacokinetic and safety study.
- Enrolled 27 infants with a median gestational age of 26 weeks.
- Population pharmacokinetic analysis of 102 plasma samples using a one-compartment model.
Main Results:
- Rifampin clearance increased with body weight and postnatal age.
- No adverse events related to rifampin were reported.
- Simulated daily intravenous dosing regimens (8 mg/kg for <14 days PNA, 15 mg/kg for ≥14 days PNA) yielded comparable exposures to adults.
Conclusions:
- Weight and postnatal age-based intravenous rifampin dosing is safe and effective in infants.
- These regimens can achieve therapeutic drug exposures similar to those in adults.
- This study provides evidence for optimized rifampin treatment strategies in neonates.
Abstract:
Rifampin is active against methicillin-resistant staphylococcal species and tuberculosis (TB). We performed a multicenter, prospective pharmacokinetic (PK) and safety study of intravenous rifampin in infants of <121 days postnatal age (PNA). We enrolled 27 infants; the median (range) gestational age was 26 weeks (23 to 41 weeks), and the median PNA was 10 days (0 to 84 days). We collected 102 plasma PK samples from 22 of the infants and analyzed safety data from all 27 infants. We analyzed the data using a population PK approach. Rifampin PK was best characterized by a one-compartment model; drug clearance increased with increasing size (body weight) and maturation (PNA). There were no adverse events related to rifampin. Simulated weight and PNA-based intravenous dosing regimens administered once daily (<14 days PNA, 8 mg/kg; ≥14 days PNA, 15 mg/kg) in infants resulted in comparable exposures to adults receiving therapeutic doses of rifampin against staphylococcal infections and TB. (This study has been registered at ClinicalTrials.gov under identifier NCT01728363.).
More Related Videos
08:58Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
Published on: October 31, 2025
11:50Clinical Practice Protocol of Creative Music Therapy for Preterm Infants and Their Parents in the Neonatal Intensive Care Unit
Published on: January 7, 2020
Related Concept Videos
Survey Safety
Long-term Depression
Household Wiring And Electrical Safety
Pharmacokinetics: Overview
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Nonlinear Pharmacokinetics: Overview
Nonlinearity can arise due to the saturation of plasma protein-binding or...